Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Kingdom Issues New Adverse Event Reporting Guidelines

This article was originally published in The Gray Sheet

Executive Summary

New guidelines spell out that manufacturers who sell medical devices in the United Kingdom have no more than two calendar days after becoming aware of a "serious public health threat" to file an initial adverse event report with the country's Medicines and Healthcare Products Regulatory Agency

You may also be interested in...



U.K. Regulatory Agency Prioritizes Safety Over International Standards Work

The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has turned its focus away from international standards work to concentrate instead on investigating medical device safety issues

U.K. Regulatory Agency Prioritizes Safety Over International Standards Work

The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has turned its focus away from international standards work to concentrate instead on investigating medical device safety issues

Revised Guidance To Clarify Adverse Event Reporting Requirements In Europe

The revision of supplemental guidelines to the European Medical Device Directive (MDD) should help further clarify manufacturer obligations for postmarket event reporting, speakers suggested March 2 at IBC Life Sciences' Vigilance & Postmarket Surveillance for Medical Devices conference in London

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel